CollectionsSanofi Pasteur
IN THE NEWS

Sanofi Pasteur

FEATURED ARTICLES
BUSINESS
May 7, 2009 | By Miriam Hill INQUIRER STAFF WRITER
The federal government has given the green light for Sanofi Pasteur Inc. to manufacture flu vaccine at its Poconos site, a boost to the country's ability to cope with future flu outbreaks. The U.S. Food and Drug Administration said it approved the facility, in Swiftwater, Pa., to produce seasonal influenza vaccine. The agency also said the facility could make a vaccine against the new 2009 H1N1 influenza strain. The Centers for Disease Control and Prevention has not yet decided whether to create a vaccine against that strain.
NEWS
July 28, 2008 | ASSOCIATED PRESS
PARIS - Sanofi-Aventis SA said its planned $551 million acquisition of Acambis PLC will bolster its leading position in the vaccine market and strengthen its development pipeline. The deal, expected to close by the end of September, would add Acambis' key smallpox vaccine ACAM2000 to the existing portfolio of Sanofi Pasteur, the vaccines business of Sanofi-Aventis. Sanofi Pasteur has a drug-development center in Malvern and facilities in Swiftwater, Pa., in the Poconos. In April, Acambis won a $425 million, 10-year contract to provide the U.S. government with its ACAM2000 vaccine, which is the mainstay of the U.S. stockpile against smallpox.
NEWS
June 16, 2008 | INQUIRER STAFF
Sanofi Pasteur, of Swiftwater in Northeastern Pennsylvania, said today it would donate 60 million doses of influenza vaccine to the World Health Organization. The vaccine, to be supplied over three years, will help build a stockpile that can be used in poor regions of the world in the event of an outbreak of pandemic influenza. Sanofi-Pasteur is the vaccines division of Sanofi-Aventis Group, the Paris pharmaceutical company. It has U.S. research and development headquarters in Malvern.
NEWS
August 26, 2010
Sanofi Pasteur said the U.S. Food and Drug Administration had accepted its application to extend the age group that can receive a vaccine that can prevent meningococcal disease. Sanofi Pasteur, the vaccines division of French drugmaker Sanofi-Aventis with U.S. headquarters in Swiftwater, Monroe County, said the FDA was reviewing its supplemental biologics license application for Menactra to be used in infants and toddlers. All of the Menactra vaccine is made in Swiftwater, said Sanofi spokeswoman Susan Watkins.
BUSINESS
November 11, 2005 | By Linda Loyd INQUIRER STAFF WRITER
Few small biotechnology companies would call ending a licensing agreement with a major pharmaceutical company a positive development. But Aphton Corp. did just that yesterday, announcing its agreement with Sanofi Pasteur was terminated to allow the smaller company to pursue another partner. Aphton and Sanofi Pasteur dissolved a licensing agreement, signed in 1997, that called for Sanofi Pasteur to copromote Aphton's cancer compound, Insegia. The move allows Aphton to seek a new partner to financially support additional clinical studies of its drug for gastric cancer.
BUSINESS
July 4, 2006 | By Thomas Ginsberg INQUIRER STAFF WRITER
Sanofi Pasteur Inc., the vaccine-maker in northeastern Pennsylvania, has found and destroyed a small amount of contaminated vaccine material at its plant, the company and regulators said yesterday. The contaminated bulk vaccine concentrate was never refined into the actual vaccine, Fluzone, or released to the public, the officials said. The company said the "unusual" contamination was discovered during a routine inspection and was reported in March to the Food and Drug Administration.
NEWS
March 13, 2014 | By Stacey Burling, Inquirer Staff Writer
Until now, hospitals have largely dealt with Clostridium difficile , a bacterial infection that bedevils vulnerable patients in health-care settings, by attempting to prevent it with intensive disinfection or treating it with antibiotics. Temple University Hospital is trying something new: a vaccine. Temple is among 200 sites in 17 countries that are testing a new vaccine produced by Sanofi Pasteur in Swiftwater, Pa. The Phase III clinical trial, known as Cdiffense, aims to recruit up to 15,000 adults.
BUSINESS
October 24, 2006 | By Thomas Ginsberg INQUIRER STAFF WRITER
Drug-safety officials and the vaccine-maker Sanofi Pasteur are studying reports of a rare paralysis condition among at least 15 young people among millions vaccinated with Menactra, its meningitis vaccine. The cases of Guillain-Barre Syndrome, occurring six weeks after vaccinations, amounted to about 1.25 people out of one million vaccinated nationwide, according to officials at the U.S. Centers for Disease Control and Prevention. An estimated 6.6 million doses of the vaccine, manufactured in Swiftwater, Pa., about 100 miles north of Philadelphia, have been administered since it was introduced in March 2005, the company said.
BUSINESS
September 16, 2005 | By Linda Loyd INQUIRER STAFF WRITER
The federal government said yesterday that it had awarded Sanofi Pasteur Inc. a $100 million contract to produce an avian flu vaccine. It also awarded GlaxoSmithKline P.L.C. a $2.8 million contract to supply its antiviral drug Relenza, which can be used to treat influenza. The Department of Health and Human Services said the contracts were part of the government's plan to buy enough vaccine for 20 million people and antivirals to treat 20 million more in the event of an avian flu pandemic.
BUSINESS
April 28, 2009 | By Miriam Hill INQUIRER STAFF WRITER
There is no vaccine against the deadly new strain of swine flu, but the federal government is pondering whether to make one. That's a tricky decision, but if the Centers for Disease Control and Prevention gives the go-ahead, it likely will turn to pharmaceutical companies with operations in this region. In the Poconos, the French vaccine-maker Sanofi Pasteur already has the capacity to churn out 50 million doses of its seasonal influenza vaccine, Fluzone, which protects against a different strain of the flu. Spokeswoman Donna Cary said the company was ready to help the CDC should the agency decide to create and manufacture a vaccine against the swine flu. The company also is close to bringing a new vaccine facility into full production at the Swiftwater, Pa., location that will double its capacity, Cary said.
1 | 2 | 3 | 4 | 5 | Next »
ARTICLES BY DATE
BUSINESS
June 22, 2016 | By Linda Loyd, Staff Writer
The first testing in people of an experimental vaccine to combat the Zika virus will begin in the next several weeks, a Philadelphia-area biotech company announced Monday. Inovio Pharmaceuticals in Plymouth Meeting and partner GeneOne Life Science in South Korea said the U.S. Food and Drug Administration has given approval to begin early-stage tests in 40 healthy adults. Shares of Inovio rose 6.97 percent, or 73 cents, to $11.20 after the announcement. The tests will be done at three U.S. locations, including Philadelphia, and will evaluate safety, tolerability, and immunogenicity of the vaccine against the mosquito-borne virus.
BUSINESS
May 25, 2016 | By Linda Loyd, Staff Writer
A small biotech company and a global vaccine maker in Southeastern Pennsylvania are among those racing to come up with a vaccine to combat the rise in the spread of the Zika virus in Brazil and other countries. The United States has yet to face a major outbreak, but concern is growing, and the Centers for Disease Control and Prevention said Friday that the number of pregnant women in the U.S. infected with the Zika virus had tripled - from 48 to 157 - due to a change in the way the government counts cases.
NEWS
November 19, 2015 | By Linda Loyd, Inquirer Staff Writer
In the days after the terrorist attacks that killed and injured hundreds in Paris, companies with major operations in France and the Philadelphia area have cautioned their employees about travel, and in at least two cases have canceled trips. Saint-Gobain Corp., a construction-materials company with 800 employees and North American headquarters in Malvern, and Arkema Inc., a chemical company in Colombes, France, that has 650 employees in King of Prussia, both advised their workers not to travel to France this week.
NEWS
September 5, 2015 | By Tom Avril, Inquirer Staff Writer
An egg shortage has driven up prices at the supermarket, caused in part by an outbreak of avian flu in the Midwest. But health officials say there is no need to worry about the supply of certain eggs outside the kitchen: the ones used to grow and incubate flu vaccine for humans. Vaccine manufacturers get their eggs from chickens raised under heightened sanitary and biosafety measures not in place in the typical shed. "It's a totally separate supply," said Lynnette Brammer, an epidemiologist with the federal Centers for Disease Control and Prevention.
NEWS
September 20, 2014 | By Stacey Burling, Inquirer Staff Writer
It is not yet flu season, but it is now officially flu shot season. Thomas Frieden, director of the Centers for Disease Control and Prevention, rolled up his sleeve at a news conference in Washington on Thursday to emphasize the need for more Americans to protect themselves and the people around them from the common, and potentially deadly, disease. He didn't flinch as the needle pierced his skin. "I hardly felt it," he said cheerfully. While Frieden predicted an ample supply of vaccine for the season, which typically runs from October through March, some local hospitals are reporting delays in shipments.
NEWS
March 13, 2014 | By Stacey Burling, Inquirer Staff Writer
Until now, hospitals have largely dealt with Clostridium difficile , a bacterial infection that bedevils vulnerable patients in health-care settings, by attempting to prevent it with intensive disinfection or treating it with antibiotics. Temple University Hospital is trying something new: a vaccine. Temple is among 200 sites in 17 countries that are testing a new vaccine produced by Sanofi Pasteur in Swiftwater, Pa. The Phase III clinical trial, known as Cdiffense, aims to recruit up to 15,000 adults.
NEWS
January 3, 2013 | By Don Sapatkin, Inquirer Staff Writer
A quadruple-dose flu vaccine for the elderly also provides better protection for people with HIV, researchers reported Tuesday in the first of several studies to publish results of high-dose vaccine for people with compromised immune systems. The team of researchers from Philadelphia institutions will ask a federal advisory committee to recommend high-dose vaccination for HIV-positive people, said Pablo Tebas, an infectious-diseases physician at the Hospital of the University of Pennsylvania and senior author of the paper in Annals of Internal Medicine.
NEWS
August 26, 2010
Sanofi Pasteur said the U.S. Food and Drug Administration had accepted its application to extend the age group that can receive a vaccine that can prevent meningococcal disease. Sanofi Pasteur, the vaccines division of French drugmaker Sanofi-Aventis with U.S. headquarters in Swiftwater, Monroe County, said the FDA was reviewing its supplemental biologics license application for Menactra to be used in infants and toddlers. All of the Menactra vaccine is made in Swiftwater, said Sanofi spokeswoman Susan Watkins.
BUSINESS
November 15, 2009 | By Miriam Hill INQUIRER STAFF WRITER
Of the companies that make the vaccine for the swine flu, only one has avoided the production problems caused by a slow-growing virus strain. AstraZeneca P.L.C.'s MedImmune Inc. is churning out nearly three million doses of its vaccine a week at its facility on Red Lion Road near the Northeast Philadelphia Airport. Production problems at other makers of H1N1 vaccine have proved to be an unintended boon for MedImmune. Other manufacturers, including Novartis AG, Sanofi Pasteur Inc., GlaxoSmithKline P.L.C.
BUSINESS
November 12, 2009 | By Miriam Hill INQUIRER STAFF WRITER
Sanofi-Aventis Group, under pressure with other vaccine-makers to meet intense public demand for flu vaccine in the United States, yesterday said it solved problems that had slowed production and was working around-the-clock to deliver the 75 million doses of H1N1 vaccine it promised the federal government by the end of December. Many employees at the company's Poconos plant here volunteered to work 12-hour shifts seven days a week, some have canceled honeymoons, and one reported to work in the afternoon after his child was born in the morning, company officials said.
1 | 2 | 3 | 4 | Next »
|
|
|
|
|